I'm thrilled to have been awarded an Alzheimer's Association Research Fellowship from Alzheimer's Association. Looking forward to expanding my research at Penn Medicine. #ENDALZ

Grant reviews have always been tough. Here's how I imagine an ancient proposal to discover coffee would have been reviewed. #AcademicTwitter OpenAcademics Academic Chatter™

On behalf of the more than 6 million Americans living with Alzheimer’s and their families, we enthusiastically welcome the positive topline data reported today on the CLARITY AD Phase 3 clinical trial of lecanemab. Read our full statement: bit.ly/3BOjqA0. #Progress (1/4)

If you're still at Society for Neuroscience (SfN) drop by and say hey this afternoon!

Check out our latest paper in Science Magazine about the mechanism of #psychedelic-induced neuroplasticity. Fantastic collaboration between Institute for Psychedelics and Neurotherapeutics labs Olson Lab, Lin Tian, PhD, John Gray, as well as @MccorvyL! science.org/doi/10.1126/sc…

Very happy to announce our manuscript examining interactions between seizures and Alzheimer's disease on neuronal E:I balance is up on bioRxiv! Thanks to David Irwin and the rest of the (twitter-less) authors for their contributions!

Poster is up! #AAIC23

Breaking: Full phase 3 results for donanemab announced today at #AAIC23 offer more hope for those living with early Alzheimer’s. Nearly half of study participants at the earliest stage of disease who received the treatment had no decline at one year. bit.ly/3NVZXDx

Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight… go.nature.com/3PSdWMV

Katalin Karikó and Drew Weissman, Penn’s historic mRNA vaccine research team, win 2023 The Nobel Prize in Medicine bit.ly/48BswPR #nobelprize

Very happy to have been a part of this project using TRAP models to examine the long-term consequences of an early life seizure on synaptic function in the adult hippocampus.

Intervention after first #seizure may prevent long-term #epilepsy @pennmedicine Journal of Clinical Investigation medicalxpress.com/news/2024-03-i…

Targeting excitatory:inhibitory network imbalance in Alzheimer’s disease New scientific commentary by David Blum & Sabine Levi tinyurl.com/3afre35m

Bakouh et al. study the mechanisms underlying epilepsy in focal cortical dysplasia, and show that somatic brain mutations in mTOR drive the deregulation of chloride co-transporters, leading to paradoxical GABA depolarization and neuronal hyperexcitability. tinyurl.com/44us42k2

Autophagy, aging, and age-related neurodegeneration. Neuron cell.com/neuron/fulltex…

Researchers have proclaimed a new era for psychiatric medicine. This new schizophrenia drug could treat Alzheimer's disease. go.nature.com/3OpYJ3Q

Dr. David Irwin, Associate Professor and Co-Director of the Penn FTD Center, was appointed chair-elect of the Scientific Program Committee to the Executive Board of Directors with the International Society for Frontotemporal Degeneration (ISFTD). Congrats Dr. Irwin! 🎉